PE20060357A1 - Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) - Google Patents

Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)

Info

Publication number
PE20060357A1
PE20060357A1 PE2005000536A PE2005000536A PE20060357A1 PE 20060357 A1 PE20060357 A1 PE 20060357A1 PE 2005000536 A PE2005000536 A PE 2005000536A PE 2005000536 A PE2005000536 A PE 2005000536A PE 20060357 A1 PE20060357 A1 PE 20060357A1
Authority
PE
Peru
Prior art keywords
phenyl
compounds
ppar
modulators
isoxazol
Prior art date
Application number
PE2005000536A
Other languages
English (en)
Inventor
Mihai Azimioara
Robert Epple
Yongping Xie
Ross Russo
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20060357A1 publication Critical patent/PE20060357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE ISOXAZOL DE FORMULA I, DONDE R1 ES ALQUILO C1-C6, CICLOALQUILO C3-C12, ARILO C6-C10, ENTRE OTROS; X ES UN ENLACE O ALQUILENO C1-C4; R2 ES -XOXOR5, -XOR5, -C(O)OR5, ENTRE OTROS; R3 ES CICLOALQUILO C3-C8, ARILO C6-C10, ENTRE OTROS; R5 ES H, ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: ACIDO (5-{4-[2-(2,4-DICLORO-FENOXI)-ETIL-CARBAMOIL]-5-FENIL-ISOXAZOL-3-IL}-FENIL)-ACETICO, ACIDO (3-CLORO-4-{4-[2-(2,4-DICLORO-FENOXI)-ETILCARBAMOIL]-5-FENIL-ISOXAZOL-3-IL}FENIL)-ACETICO, ACIDO (3-CLORO-4-{4-[2-(2,4-DICLORO-FENOXI)-ETILCARBAMOIL]-5-p-TOLIL-ISOXAZOL-3-IL}-FENIL)-ACETICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A COMPOSICIONES FARMACEUTICAS. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR ACTIVADO DE PROLIFERADOR DE PEROXISOMA (PPAR), PARTICULARMENTE LA ACTIVIDAD DE PPARd Y SON UTILES PARA EL TRATAMIENTO DE DISLIPIDEMIA, ATEROSCLEROSIS, FALLA CARDIACA, ENFERMEDADES VASCULARES, ENTRE OTRAS
PE2005000536A 2004-05-14 2005-05-13 Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) PE20060357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57100304P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
PE20060357A1 true PE20060357A1 (es) 2006-05-09

Family

ID=35428368

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000536A PE20060357A1 (es) 2004-05-14 2005-05-13 Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)

Country Status (14)

Country Link
US (1) US7820705B2 (es)
EP (1) EP1745027A4 (es)
JP (1) JP2007537286A (es)
KR (1) KR20070034993A (es)
CN (1) CN1984894A (es)
AR (1) AR048789A1 (es)
AU (2) AU2005245411B2 (es)
BR (1) BRPI0511099A (es)
CA (1) CA2564429A1 (es)
MX (1) MXPA06013196A (es)
PE (1) PE20060357A1 (es)
RU (1) RU2408589C2 (es)
TW (1) TW200602330A (es)
WO (1) WO2005113519A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
WO2007011524A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
WO2007050485A2 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
DE102006014165A1 (de) * 2006-03-24 2007-09-27 Schebo Biotech Ag Neue Isooxazol-Derivate und deren Verwendungen
AR060901A1 (es) * 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
AU2008333326B2 (en) 2007-12-04 2013-05-30 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
AU2008333320B2 (en) * 2007-12-04 2012-12-20 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
ES2714453T3 (es) * 2008-06-09 2019-05-28 Univ Muenchen Ludwig Maximilians Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105030771B (zh) * 2015-04-10 2017-11-17 广州市爱菩新医药科技有限公司 连吡啶异恶唑类化合物作为法尼醇x受体激动剂的应用
CN105622536B (zh) * 2015-12-30 2018-06-29 商丘师范学院 一种三氟甲基化烯基异噁唑化合物及其制备方法和应用
CN105622537A (zh) * 2016-03-01 2016-06-01 青岛大学 一种3,4,5-三取代异恶唑类化合物的合成方法
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
AU2020209564B2 (en) 2019-01-15 2022-12-01 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2088996A (en) * 1935-11-22 1937-08-03 Hoffmann La Roche Double compounds of secondary amides of 3.5-dimethyl-isoxazole-4-carboxylic acid and process for the manufacture of same
DE1670249B2 (de) * 1966-07-25 1974-07-18 Bristol-Myers Co., East Syracuse, N.Y. (V.St.A.) Verfahren zur Herstellung von 4-Isothiazolcarbonsäuren
GB1203040A (en) 1967-02-15 1970-08-26 Geigy Ag J R 5-nitro-2-furyl-isoxazoles and compositions thereof
US3466296A (en) 1967-05-16 1969-09-09 American Home Prod Process for the preparation of alkyl 3,5-disubstituted-isoxazole-4-carboxylates
DE3247454A1 (de) 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
IT1228288B (it) 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica
DE4219247A1 (de) * 1992-06-12 1993-12-16 Bayer Ag Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung
CA2247439A1 (en) 1996-02-27 1997-09-04 Sankyo Company, Limited Isoxazole derivatives
US6369070B1 (en) * 1998-04-08 2002-04-09 Eli Lilly And Company Methods for inhibiting mrp1
ES2255294T3 (es) * 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
WO2001016116A1 (en) * 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolines and isoxazoles
WO2001096346A1 (en) * 2000-06-14 2001-12-20 Eli Lilly And Company Tricyclic compounds as mrp1-inhibitors
GB0119911D0 (en) * 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2004024939A2 (en) 2002-09-13 2004-03-25 Georgetown University Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
ATE399165T1 (de) * 2003-09-12 2008-07-15 Rigel Pharmaceuticals Inc Chinolinverbindungen und deren verwendungen

Also Published As

Publication number Publication date
EP1745027A1 (en) 2007-01-24
AU2005245411A1 (en) 2005-12-01
US20080114044A1 (en) 2008-05-15
WO2005113519A1 (en) 2005-12-01
EP1745027A4 (en) 2009-06-03
AU2005245411B2 (en) 2009-04-23
CA2564429A1 (en) 2005-12-01
AU2009202781A1 (en) 2009-07-30
US7820705B2 (en) 2010-10-26
JP2007537286A (ja) 2007-12-20
MXPA06013196A (es) 2007-02-14
RU2006144124A (ru) 2008-06-20
BRPI0511099A (pt) 2007-12-26
RU2408589C2 (ru) 2011-01-10
TW200602330A (en) 2006-01-16
KR20070034993A (ko) 2007-03-29
CN1984894A (zh) 2007-06-20
AR048789A1 (es) 2006-05-24

Similar Documents

Publication Publication Date Title
PE20060357A1 (es) Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20061013A1 (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
PE20061290A1 (es) Derivados de 1-benzil-indol-2-carboxamida
PE20060362A1 (es) Compuestos de oxazol como moduladores de ppar
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20060657A1 (es) Derivados de pirimidina como moduladores de ppar-alfa
PE20050628A1 (es) DERIVADOS DE 2-AMINO-PIRIDINA COMO AGONISTAS ß-2
JP2016528201A5 (es)
CA2536136A1 (en) Aryloxy and arylalkyleneoxy substituted imidazoquinolines
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
AR048306A1 (es) Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40
PE20080552A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20090815A1 (es) Compuesto de amida
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20212070A1 (es) Moduladores de trex1
PE20120307A1 (es) Derivados de indazol como antagonistas del receptor ccr4
EA025199B1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
PE20071062A1 (es) Antibioticos de carbonatos de fenicol
PE20120362A1 (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapia
RU2008129635A (ru) Ингибиторы ссr9 активности
PE20120688A1 (es) Derivados de n1-acil-5-fluoropirimidinona
AR077227A1 (es) Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende
EA202190302A1 (ru) Соединения 2,6-диаминопиридина
CL2022003625A1 (es) Compuestos naftaleno isoxazolina para controlar plagas invertebradas (divisional de patente de invención no 2073-2020)

Legal Events

Date Code Title Description
FC Refusal